A5046086752- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Agricultural pest management studies
- Colorectal Cancer Treatments and Studies
- Antimicrobial Peptides and Activities
- Melanoma and MAPK Pathways
- Insect Pest Control Strategies
- Cancer, Stress, Anesthesia, and Immune Response
- Inflammatory mediators and NSAID effects
- Insect-Plant Interactions and Control
- Prostate Cancer Treatment and Research
Copenhagen University Hospital
2020-2021
Gentofte Hospital
2017-2019
University of Copenhagen
2018-2019
Herlev Hospital
2019
Evergen Biotechnologies (United States)
2016
Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study, we investigated whether immune system progressing following CPI treatment was able to generate functional tumor-specific responses.Tumor-infiltrating lymphocytes (TILs) were isolated and expanded lesions which progressed during after anti-programmed cell death protein 1 (PD)-1 anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) treatment....
Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune‐related adverse events (irAEs). Immunosuppression high dose corticosteroids, tumor necrosis factor (TNF) antagonists in refractory cases, is the mainstay treatment for irAEs. It currently unknown what impact corticosteroids and anti‐TNF have on activity antitumor T cells. In our study, influence clinically relevant doses dexamethasone (corresponding an oral 10–125 mg prednisolone) infliximab...
Background: Human intratumoral T cell infiltrates can be defined by quantitative or qualitative features, such as their ability to recognize autologous tumor antigens. In this study, we reproduced the tumor-T interactions of individual patients determine and compared characteristics across multiple types. Methods: We employed 187 pairs unselected tumor-infiltrating lymphocytes (TILs) cells from with melanoma, renal-, ovarian-cancer sarcoma, single-cell RNA sequencing data a pooled cohort 93...
Detecting the entire repertoire of tumor-specific reactive tumor-infiltrating lymphocytes (TILs) is essential for investigating their immunological functions in tumor microenvironment. Current vitro assays identifying functional activation measure upregulation surface molecules, de novo production antitumor cytokines, or mobilization cytotoxic granules following recognition tumor-antigens, yet there no widely adopted standard method. Here we established an enhanced, simple, method...
Abstract Studies have shown that smoking is associated with both greater incidence and worse outcomes of prostate cancer. The mechanism involved in this adverse effect cigarette smoke on cancer cells not known. We hypothesized condensate (CSC) would an vitro cell proliferation motility. CSC the tar phase particulate. submitted PC-3 for assays after 4 24 hours exposure to varying concentrations CSC. also performed motility probed epithelial mesenchymal transition (EMT) using...
Abstract Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune-related adverse events (irAEs). Immunosuppression high doses corticosteroids or, in refractory cases, tumor necrosis factor (TNF) antagonists, are the mainstay treatment for irAEs. It is currently unknown what impact and anti-TNF on activity antitumor T cells. In this study, influences clinically relevant dexamethasone (corresponding an oral dose 10 125 mg prednisolone) infliximab...
Background: Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune-related adverse events (irAEs). Immunosuppression high doses corticosteroids or, in refractory cases, tumor necrosis factor (TNF) antagonists, are the mainstay treatment for irAEs. It is currently unknown what impact and anti-TNF on activity tumor-specific T cells. Methods: The influence clinically relevant dexamethasone (corresponding an oral dose 10 125 mg prednisolone) infliximab...
Abstract Background: Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune-related adverse events (irAEs). Immunosuppression high doses corticosteroids or, in refractory cases, tumor necrosis factor (TNF) antagonists, are the mainstay treatment for irAEs. It is currently unknown what impact and anti-TNF on activity antitumor T-cells. Methods: The influence clinically relevant dexamethasone (corresponding an oral dose 10 125 mg prednisolone)...